. 2020 Oct 21;15(10):e0240584. doi: 10.1371/journal.pone.0240584

Table 2. Summary of analyses completed.

Outcome	Treatment durations analyzed	Type of measure	No. of trials^*	No. of participants	Duration (range, wk)
BENEFITS^£
Patient-reported clinical response	≥12 wk	Continuous	9	1462	12–52
Patient-reported clinical response	≥12 wk	Dichotomous	4	322	12–24
Clinician-reported clinical response	≥12 wk	Continuous	15	3365	12–52
Clinician-reported clinical response	≥12 wk	Dichotomous	8	1902	12–24
Quality of Life^†	≥12 wk	Continuous	5^‡	1862	12–26
Executive Function^†	Any duration^**	Continuous	11	3024	2–10
HARMS
Serious adverse events^†	≥12 wk	Dichotomous	5	1380	12–24
Serious adverse events^†	Any duration	Dichotomous	33	7161	1–24
Withdrawals due to adverse events^†	≥12 wk	Dichotomous	16	3650	12–52
Withdrawals due to adverse events^†	Any duration	Dichotomous	52	10726	2–52
Treatment discontinuation^†	≥12 wk	Dichotomous	16	3568	12–26
Treatment discontinuation^†	Any duration	Dichotomous	51	9959	3–26

* Data are for trials included in analyses. Two included publications each reported data from two unique trials, thus, the number of trials is greater than the number of included publications.

^£ Patient and clinician-reported clinical response were analyzed by both pairwise meta-analysis and Bayesian network meta-analysis; quality of life and executive function were analyzed by pairwise meta-analysis only.

†Analyzed by pair-wise meta-analysis.

‡All studies involved atomoxetine.

**No studies with a treatment duration of at least than 12 weeks assessed executive function.